S-1/A: Bone Biologics Eyes $10.375 Million Capital Raise Through Securities Offering

Bone Biologics Corporation aims to raise capital through an offering of common stock, warrants, and pre-funded warrants, targeting clinical trials and patent portfolio expansion.

Summary

• Bone Biologics Corporation is planning to offer up to 1,282,051 shares of common stock along with warrants to purchase an equal number of shares.
• The assumed combined public offering price is $3.90 per share and accompanying warrant.
• Warrants will have an assumed exercise price of $3.90 per share and expire five years from issuance.
• The company is also offering pre-funded warrants for investors who would exceed beneficial ownership limits (4.99% or 9.99%).
• Each pre-funded warrant is sold with one warrant to purchase one share of common stock, with the price equal to the combined offering price minus $0.001.
• H.C. Wainwright & Co., LLC is acting as the exclusive placement agent for the offering.
• The placement agent will receive a cash fee of 7.0% of the gross proceeds, a management fee of 1.0%, and warrants to purchase 6.0% of the shares sold in the offering at an assumed exercise price of $4.88 per share.
• The offering will terminate on May 13, 2024, unless terminated earlier by the company.
• Net proceeds are intended to fund clinical trials, maintain and extend the patent portfolio, and for working capital.
• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company is attempting to raise capital for future growth, the going concern warning from the auditor and the inherent risks of the business temper any optimism.

Positives

• The offering aims to secure funding for critical clinical trials and patent protection.
• The company has engaged a placement agent to facilitate the offering.
• Pre-funded warrants offer flexibility for investors with ownership limitations.

Negatives

• The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• The offering may dilute existing shareholders' equity.
• There is no guarantee that the company will raise the full amount of the offering.
• The company has a history of operating losses and expects to incur additional losses in the near term.

Risks

• The company's ability to continue as a going concern is uncertain.
• The offering may not raise sufficient capital to meet the company's needs.
• Clinical trials may not be successful.
• The company may not be able to obtain regulatory approval for its products.
• The company faces competition from other companies in the medical device industry.
• The company is dependent on third-party suppliers and manufacturers.
• The company's intellectual property may not be sufficient to protect its products from competition.
• The company may be subject to product liability lawsuits.

Future Outlook

The company intends to use the net proceeds from this offering to fund clinical trials, maintain and extend its patent portfolio, and for working capital and other general corporate purposes. The company will need to raise additional capital to fund its operations and continue to support its planned development and commercialization activities.

Industry Context

The company operates in the medical device industry, specifically focusing on bone regeneration in spinal fusion. The global bone graft substitute market presents a $3 billion market opportunity. The company believes its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Comparison to Industry Standards

• The document mentions that while use of the patient's own bone (autograft) remains the optimal treatment for spinal fusion, complications limit its use.
• The company believes that NELL-1 technology is expected to perform as well as other growth factors in the non-union trauma cases market.
• The document does not provide specific comparisons to industry standards or comparable companies.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• Employees' job security may be affected by the company's financial performance.
• Customers may benefit from the development of new products.
• Suppliers may see increased business if the company is successful.
• Creditors face increased risk due to the company's financial situation.

Next Steps

• The company will proceed with the offering, seeking to secure funding for clinical trials and patent protection.
• The company will need to maintain compliance with Nasdaq listing standards.
• The company will need to manage its cash flow and secure additional funding in the future.

Key Dates

Keywords

warrants, pre-funded warrants, common stock, offering, Bone Biologics, capital raise, clinical trials, patent portfolio, BBLG, securities